According to the results of clinical trials, published in the journal The Lancet, the inclusion of bortezomib in the standard treatment of the two products extend the life of patients with multiple myeloma.
Researchers from the international network of clinical oncology trials sponsored by the National Cancer Institute, compared the efficacy of two treatment regimens in newly diagnosed patients undergoing the first stage of the treatment of multiple myeloma, bone marrow cancer varieties. One drug regimen used in the study - Lenalidomide plus dexamethasone, the standard first-line therapy. Another mode includes bortezomib, second-line drug, commonly assigned myeloma patients whose cancer progressed following initial therapy.
The researchers found that the addition of bortezomib has significant difference for patients with myeloma - a year of remission, and another year of life. Patients receiving bortezomib along with lenalidomide and dexamethasone, in the first six months of treatment duration of remission was 43 months compared to 30 months of remission in patients not receiving the drug.
The results of research and new treatments are very important, because it helps patients with myeloma to stay healthy longer and allows you to spend more time with loved ones. This is a new standard of care, "- said principal investigator Brian JM Durie, MD and chairman of the International Myeloma Foundation Board.
Results of the study for the first time attracted attention in December 2015 at the 57th Annual Meeting of the American Society of Hematology, held in Florida. Myeloma - the second most common type of blood cancer in the world. According to statistics, in 2016 diagnosed 30.330 new cases of myeloma. In recent years, new drugs that have given new hope, and life expectancy for people with this diagnosis is slowly growing.
Researchers drew 471 adult patients from February 2008 to February 2012 in 139 institutions.
Patients were 28 to 87 years with active myeloma did transplant of stem cells and treatment was not performed prior disease. The patients were divided into two groups. The first received the standard treatment in the form of two drugs for six cycles for six months. Another group was given three drugs that included bortezomib, proteasome inhibitor, for eight cycles, also for six months.
Despite the increase in life expectancy and remission by combination of the three drugs have side effects: tingling, pain, numbness, and weakness in the arms and legs.